Skip to main content

Table 1 Total Medication Cost of Patients with MS in 2019–20

From: Estimation the medical cost of multiple sclerosis in Iran; 2019–2020

Drug Generic Name Number of Patients received MS medications (IHIO) Total Drug Cost (1000 $) Copayment Share (%) Out of Pocket (1000 $) IHI Cost share (1000 $) Cost Per Patient ($) OOP per Patients ($) Estimate of Country Total Cost (1000 $) Share in the Total Cost (%)
Beta-Interferon 21,019 56,280.1 13 7316.4 48,963.7 2677.5 348.08 112,560.3 58.53
Glatiramer Acetate 1434 4251.1 10 425.1 3826.06 2964.5 296.4 8502.3 4.42
Dimethyl Fumarate 8779 7546.4 30 2263.9 5282.5 859.6 257.8 15,092.9 7.84
Fingolimod 7333 7585.4 5 379.2 7206.1 1034.4 51.7 15,170.8 7.88
Teriflunomide 1553 1540.8 30 462.2 1078.5 992.1 297.6 3081.6 1.60
Rituximab 9506 13,470.7 10 1347.07 12,123.7 1417.08 141.7 26,941.5 14.01
Natalizumab 724 5459.05 10 545.9 4913.1 7540.1 754.01 10,918.1 5.67
Cyclophosphamide 192 6.37 10 0.63 5.73 33.1 3.3 12.7 0.006
Mitoxantrone 102 8.88 10 0.88 8 87.1 8.7 17.7 0.009
Total 50,642 96,149.19 13.25 12,741.51 83,407.68 17,605.87 2159.54 192,298.38 100